---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000119"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-08-11T11:33:42+00:00"
generated_at: "2026-08-11T11:35:08.072337+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Autolus Q2 revenue up 119% to $45.7M; FY26 guidance raised to $140-150M

## Summary
- Q2 2026 net product revenue $45.7M vs $20.9M YoY (+119%); Q1 2026 was $26.2M.
- Gross margin jumped to 55% in Q2 from 6% in Q1 2026 on higher volumes and cost cuts.
- Net loss narrowed to $39.1M ($0.15/sh) from $47.9M ($0.18/sh) in Q2 2025.
- Closed $75M tranche of up to $250M five-year interest-only Perceptive Advisors credit facility.
- Workforce reduction ~13% to save ~$15M annual opex; cash $201.6M at June 30, 2026.

## SEC filing metadata
- accession: 0001730463-26-000119
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-08-11T11:33:42+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/0001730463-26-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autl-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000119
- JSON: https://secwatch.observer/filing/0001730463-26-000119.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.